Sarepta is on the brink of a considerable breakout and the NASDAQ:ARRY deal yesterday has just added more fuel to the fire. Currently sitting just below the 200ma and the $128 price level,a break above looks inevitable and all indicators are very bullish with the RSI aalso breaking out.
AVERAGE ANALYSTS PRICE TARGET $204 AVERAGE ANALYSTS RECOMMENDATION BUY P/E RATIO SHORT INTEREST 15%
COMPANY PROFILE Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.